Section One: Overview and Determination

Please find below a statement of our determination as to whether or not the committee views Aromatherapy as a proven and effective treatment for children with autism spectrum disorder and/or other developmental disabilities. In subsequent sections you will find documentation of our review process including a description of the proposed treatment, a synopsis of review findings, the treatment review evidence checklist, and a listing of the literature considered. In reviewing treatments presented to us by DHS/DLTC, we implement a review process that carefully and fully considers all available information regarding a proposed treatment. Our determination is limited to a statement regarding how established a practice is in regard to quality research. We do not make funding decisions.

Description of proposed treatment
Aromatherapy is defined on the National Association for Holistic Aromatherapy website as “… the art and science of utilizing naturally extracted aromatic essences from plants to balance, harmonize and promote the health of body, mind and spirit. It seeks to unify physiological, psychological and spiritual processes to enhance an individual’s innate healing process.” Aromatherapy uses essential oils from plants such as lavender plus other aromatic compounds to alter mood, anxiety, stress, etc., and is reported to improve conditions ranging from pain to inattention to anxiety and stress.

Aromatherapy belongs to the group of complementary or alternative medicine that is often given concurrent with traditional medicine, but can be given alone. Generally speaking, the evidence for aromatherapy is not convincing and weakens as experimental controls are improved.

Synopsis of review
In the case of Aromatherapy, please refer to the attached reference listing that details the reviewed research. The committee’s conclusions regarding Aromatherapy include:

1. Weak research designs that confounds variables and insensitive data collection/interpretation practices to yield questionable data that is used to support arguments for its efficacy.
2. Lack of adequate control groups (e.g., a placebo) are common.
3. No studies were found that compared aromatherapy with mainstream medical practices alone or in combination with aromatherapy - a critical concern for a therapy claiming to be “complementary” medicine.
4. Inconsistent replication across researchers.
5. Data collection procedures that are insensitive to the dependent variables.
6. In addition, data are emerging (e.g., Podsadzki, Alotaibi, & Ernst; 2012) that aromatherapy can have adverse side effects that, in rare cases, is fatal. That and the problems with identifying convincing data in any of numerous reviews, leads to the conclusion that aromatherapy has enjoyed unjustified wide-spread application.

In sum, it is the decision of the committee that (a) authorities are in substantive disagreement concerning aromatherapy’s efficacy. Reviews consistently find research methodology concerns that question whole bodies of evidence. Aromatherapy has not been systematically studied with ASD, emerging evidence exists that it may be harmful, and comparative studies with proven procedures do not exist. Consequently, a Level 4 designation (Insufficient Evidence/Experimental Treatment) is recommended.
Section Two: Rationale for Focus on Research Specific to Comprehensive Treatment Packages (CTP) or Models

In the professional literature, there are two classifications of interventions for individuals with Autism Spectrum Disorder (National Research Council, 2001; Odom et al., 2003; Rogers & Vismara, 2008):

(a) **Focused intervention techniques** are individual practices or strategies (such as positive reinforcement) designed to produce a specific behavioral or developmental outcome, and

(b) **Comprehensive treatment models** are “packages” or programs that consist of a set of practices or multiple techniques designed to achieve a broader learning or developmental impact.

To determine whether a treatment package is proven and effective, the Treatment Intervention Advisory Committee (TIAC) will adopt the following perspective as recommended by Odom et al. (2010):

The individual, focused intervention techniques that make up a comprehensive treatment model may be evidence-based. The research supporting the effectiveness of separate, individual components, however, does *not* constitute an evaluation of the comprehensive treatment model or “package.” The TIAC will consider and review only research that has evaluated the efficacy of implementing the comprehensive treatment *as a package*. Such packages are most often identifiable in the literature by a consistently used name or label.


Section Three: DLTC-TIAC Treatment Review Evidence Checklist

Name of Treatment: Aromatherapy

Level 1 - Well Established or Strong Evidence (DHS 107 - Proven & Effective Treatment)

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, National Professional Development Center) have approved of or rated the treatment package as having a strong evidence base; authorities are in agreement about the level of evidence.

☐ There exist ample high quality studies that demonstrate experimental control and favorable outcomes of treatment package.
  ☐ Minimum of two group studies or five single subject studies or a combination of the two.
  ☐ Studies were conducted across at least two independent research groups.
  ☐ Studies were published in peer reviewed journals.

☐ There is a published procedures manual for the treatment, or treatment implementation is clearly defined (i.e., replicable) within the studies.

☐ Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: At this level, include ages of participants and disabilities identified in body of research

Level 2 – Established or Moderate Evidence (DHS 107 - Proven & Effective Treatment)

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have approved of or rated the treatment package as having at least a minimal evidence base; authorities may not be in agreement about the level of evidence.

☐ There exist at least two high quality studies that demonstrate experimental control and favorable outcomes of treatment package.
  ☐ Minimum of one group study or two single subject studies or a combination of the two.
  ☐ Studies were conducted by someone other than the creator/provider of the treatment.
  ☐ Studies were published in peer reviewed journals.

☐ Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: At this level, include ages of participants and disabilities identified in body of research
Level 3 – Emerging Evidence (DHS 107 – Promising as a Proven & Effective Treatment)

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have recognized the treatment package as having an emerging evidence base; authorities may not be in agreement about the level of evidence.

☐ There exists at least one high quality study that demonstrates experimental control and favorable outcomes of treatment package.

☐ May be one group study or single subject study.

☐ Study was conducted by someone other than the creator/provider of the treatment.

☐ Study was published in peer reviewed journal.

☐ Participants (i.e., N) are clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: At this level, include ages of participants and disabilities identified in body of research

Level 4 – Insufficient Evidence (Experimental Treatment)

☒ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence.

☒ There is not at least one high quality study that demonstrates experimental control and favorable outcomes of treatment package.

☐ Study was conducted by the creator/provider of the treatment.

☐ Study was not published in a peer reviewed journal.

☒ Participants (i.e., N) are not clearly identified as individuals with autism spectrum disorders or developmental disabilities.

Notes: (a) Data suggests that harmful effects have been documented, and (b) No systematically completed series of studies indicates that aroma therapy is efficacious in comparison research, where proper control groups are in place, and where data collection procedures are sensitive to behaviors that are clearly identified as dependent variables.
Level 5 – Untested (Experimental Treatment) &/or Potentially Harmful

☐ Other authoritative bodies that have conducted extensive literature reviews of related treatments (e.g., National Standards Project, NPDC) have not recognized the treatment package as having an emerging evidence base; authorities are in agreement about the level of evidence.

☐ There are no published studies supporting the proposed treatment package.

☐ There exists evidence that the treatment package is potentially harmful.
  ☐ Authoritative bodies have expressed concern regarding safety/outcomes.
  ☐ Professional bodies (i.e., organizations or certifying bodies) have created statements regarding safety/outcomes.

Notes:

Date: January 29, 2016

Committee Members Completing Initial Review of Research Base: Roger Bass, Lana Collet-Klingenberg

Committee Decision on Level of Evidence to Suggest the Proposed Treatment is Proven and Effective: Level 4 – Insufficient Evidence (Experimental Treatment)

References Supporting Identification of Evidence Levels:


Section Four: Literature Review


